within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AF12_Clevudine;

model Clevudine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.7,
    Cl = 4.444444444444444e-06,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.075,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.018333333333333333,
    Tlag = 10.020000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Clevudine</td></tr><tr><td>ATC code:</td><td>J05AF12</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>75</td><td>L</td></tr>
    <tr><td>clearance:</td><td>16</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Clevudine is a nucleoside analog antiviral drug primarily developed for the treatment of chronic hepatitis B virus (HBV) infection. It inhibits DNA synthesis of HBV by acting as a reverse transcriptase inhibitor. Clevudine is not currently approved for use in the United States or many other major markets, but was approved and used in certain Asian countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult healthy volunteers and patients with chronic hepatitis B following oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AF12 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Clevudine;
